Organogenesis Holdings Inc. provided earnings guidance for the fiscal year ending December 31, 2022. For the year, the company expects net revenue of between $465 million and $490 million, representing a decrease of approximately 1% to an increase of 5% year-over-year, and 2% to 7% on an adjusted basis, as compared to net revenue of $467.4 million for the year ended December 31, 2021. Net income in a range of approximately $26 million to $36 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 USD | +1.63% | +0.20% | -38.88% |
May. 13 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
May. 10 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.88% | 331M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
-12.11% | 26.22B | |
+12.62% | 26.36B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022